cyrilzakka/clinical-trials huggingface dataset:
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).


Eligibility Criteria:
Inclusion Criteria:

* Patient meeting inclusion criteria of the French Système national d'information inter-régimes de l'assurance maladie (SNIIR-AM)/Programme de médicalisation des systèmes d'information (PMSI) claim databases (Patient insured by the French national health insurance general scheme stricto sensu (apart from local mutualist sections)
* Patients with at least one reimbursement of AC treatment (acenocoumarol, warfarine and fluidione for VKA treatments, apixaban, dabigatran or rivaroxaban for New oral anticoagulants (NOACs)) treatments during the inclusion period
* Patients initiated with a new AC treatment during the inclusion period, either AC naive or not
* Patients aged 18 or older at their first anticoagulant initiation during the inclusion period
* Patient diagnosed with non-valvular Atrial fibrillation (AF)
Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients

The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).


Eligibility Criteria:
Inclusion Criteria:

* 120 epilepsy patients from the epilepsy clinic and Emergency Room (ER)
* Controls: 100 patients with other neurological diseases and no epilepsy; and 30 healthy volunteers.
Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Stiffening of your blood vessels, particularly the large vessels from your heart (called the aorta and carotids) you age contributes to the development of cardiovascular disease (CVD) such as heart attack and stroke. Nerve activity from your brain to your body also increases with advancing age but it is unknown if this nerve activity contributes directly to the stiffening on your blood vessels in older adults in addition to high blood pressure. Therefore, successful completion of the proposed aims will have a significant clinical impact by identifying if nerve activity from your brain could be a novel target for therapies that would lower stiffness of the aorta and carotid arteries in older adults.


Eligibility Criteria:
Inclusion Criteria:

* age 60-85
* non-smoking
* clinically healthy
* untreated or treated stage 1 isolated systolic hypertension (ISH) (systolic BP 130-139 mmHg; diastolic BP \<90 mmHg) or stage 2 ISH (systolic BP 140-159 mmHg; diastolic BP \<90 mmHg) per 2017 AHA/ACC hypertension guidelines
* if subject is on antihypertensive medications, they will stop taking medication for a one-week washout period after Visit 1 before they return for Visit 2. They will come in at day 3 and day 7 of the one-week washout for a BP reading, to confirm that systolic BP is \<160 mmHg.

Exclusion Criteria:

* no history of cardiovascular disease (e.g., myocardial infarction, bypass surgery, angioplasty/stent, heart failure, cardiomyopathy, pacemaker/defibrillator, peripheral artery disease), pulmonary disease, liver disease, Type I or II diabetes, cancer (treated by chemotherapy and/or radiation), psychiatric illness, on aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
* aspirin, NSAIDs, vitamins, herbal supplements, omega-3-fatty acids will have to discontinue for at least 1 week before participation and remain discontinued during the study.
* blood thinners, serotonin reuptake inhibitors (SSRIs), or PDE5 inhibitors will also be excluded.
* Women must be postmenopausal for at least 6 months (surgical or natural) and not currently on hormone replacement therapy.
* Subjects not on antihypertensive will not be eligible if their resting clinic systolic BP is \<130 mmHg or \>160 mmHg and diastolic BP \>90 mmHg.
Prevalence of ENT Diseseas

The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of long-COVID symptoms and further, to evaluate different factors that influence on the one hand the prevalence (urban-bred, non-urban-bred) and on the other hand symptoms (ENT-surgeries in medical history). Further, we want to evaluate if there is a correlation between subjective symptoms and apparated-based diagnostic investigations.

Therefore, questionnaires and data of medical examinations, aquired routinely at the military induction board, will be analysed.

Rhinosinusitis is a very common complaint at ENT departments, whereby symptoms of the underlying disease are varying. Therefore, there is growing interest in prevalence of rhinosinusitis including differences in prevalence's depending on where the patient grew up. Further, there is growing interest in answering the question if different factors, including ENT-surgeries in medical history have an impact on symptoms of rhinosinusitis.

Within the past few years there is growing interest in carring out as many HPV-vaccinations as possible in order to reduce the prevalence of HPV-associated cancers.

Further, in adolescents there is a growing number of hearing impairments, including hearing loss and/or sounds in the ears.

Next, since the beginning of the COVID pandemic there are very common complaints in adult and pediatric patients about persistent medical problems for weeks or months after an acute SARS-CoV-2-infection and cannot be explained by another diagnosis, called long- Covid disease.

The military induction board of conscripts enables access to data from a cross-section of the population, with common characteristics of gender and age.

In the present study we want therefore to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of long-COVID symptoms and further, to evaluate different factors that influence on the one hand the prevalence (urban-bred, non-urban-bred) and on the other hand symptoms (ENT-surgeries in medical history). Further, we want to evaluate if there is a correlation between subjective symptoms and apparated-based diagnostic investigations.

Eligibility Criteria:
Inclusion Criteria:

* participation of the military induction board of conscripts
* consent for participation obtained by the conscripts
* completed questionnaire (with at least 50% completeness of each subcategory)
* participation of medical examination

Exclusion Criteria:

* no consent for participation in the study by the conscripts
* incomplete questionnaire (with less than 50% completeness of each subcategory)
* no participation of medical examination.
Transition From Hospital to Home in Solid Organ Transplant (SOT)

The aim of this study is to determine the influences of discharge teaching and care coordination on how ready a parent is to take their child home from the hospital after a solid organ (kidney, heart and liver) transplant. This study will also look into how the parent handles coping, utilization of healthcare resources, and parent adjustment 3 weeks after discharge from the hospital.

Parents of children that have received a heart, kidney or liver transplant will be asked to participate in this protocol. Involvement in this study involves completion of questionnaires prior to the child being discharged from the hospital. Three weeks after discharge, there will also be a follow-up phone call to complete more questionnaires.

Readiness for hospital discharge is a under-investigated topic in pediatric solid organ transplant patients, despite the increasing number of pediatric patients undergoing transplant surgery. Results from this study will be used to develop an intervention program to promote readiness for hospital discharge in parents of children who receive a solid organ transplant.

Eligibility Criteria:
Inclusion Criteria:

* parents of children who have undergo a heart, kidney, or liver transplant
* English Speaking
* Parents are 18 years of age or older

Exclusion Criteria:

* parents with significant cognitive or communication impairment that would not allow them to complete the questionnaires
* parent whose child is receiving their 2nd or 3rd organ transplant
A Study of Dideoxycytidine in HIV-Infected Patients

To determine how much of a dose is absorbed by the body when zalcitabine ( dideoxycytidine; ddC ) is given orally and how long the drug stays in the body after absorption or intravenous (IV) administration.

Laboratory tests have shown that ddC is effective in stopping the growth of the HIV in test tubes. The study will reveal the pharmacokinetic (blood levels) properties of this new drug and how long the drug remains in the body at each of six doses. This should be useful background information and should allow a simple and efficient comparative study of any new oral formulation, such as a tablet or capsule, since dose-related problems will already be known.

Laboratory tests have shown that ddC is effective in stopping the growth of the HIV in test tubes. The study will reveal the pharmacokinetic (blood levels) properties of this new drug and how long the drug remains in the body at each of six doses. This should be useful background information and should allow a simple and efficient comparative study of any new oral formulation, such as a tablet or capsule, since dose-related problems will already be known.

Patients are hospitalized and receive ddC twice, once by mouth and once by IV injection. Each patient receives the drug at one of six increasing doses, and no patient is studied at more than one dose level. Following each dose, toxicity is measured before the next higher dose is given. Several blood samples and urine specimens are taken to permit measurement of the amount of drug in the bloodstream and of the speed with which it is eliminated from the body.

Eligibility Criteria:
Inclusion Criteria

Prior Medication:

Allowed:

* Oral nonabsorbable antifungal agents.

Exclusion Criteria

* Active drug or alcohol abuse.

Co-existing Condition:

* Patients with fever \> 102 degrees F at study entry will be excluded.
* Patients with fever \> 102 degrees F at study entry will be excluded.

Prior Medication: Excluded:

* Chronic systemic medications.
* Any other experimental drug within 2 weeks of study entry.
* Drugs with known nephrotoxic or hepatotoxic effects within 2 weeks of study entry.
* Drugs known to cause neutropenia within 2 weeks of study entry.
* Rifampin or rifampin derivatives, phenytoin, or barbiturates within 2 weeks of study entry.
* Any other medication except oral nonabsorbable antifungal agents within 72 hours of study entry.

All medications, including aspirin, must be approved by investigator. All medications, including aspirin, must be approved by investigator.

Patients must demonstrate the following clinical and laboratory findings:

* AIDS, AIDS related complex (ARC), or persistent generalized lymphadenopathy as defined by the CDC classification.
* No ascites.
* Off all medications except oral antifungal, nonabsorbable agents for 72 hours prior to study entry.
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

The study induces an immune response towards the stem-cell like part of glioblastomas in combination with standard therapy. The aim is to define and characterize the feasibility, potential adverse effects of such therapy and measure time to progression and survival.


Eligibility Criteria:
Inclusion Criteria:

* Accessible volume and quality of tumor tissue for vaccine production
* MRI after surgery with minimal tumor remnant.
* Between 18 and 70 years of age.
* Must have histologically confirmed glioma grade IV, and a candidate for combined radiation therapy and chemotherapy ("Stupps regimen").
* Must be ambulatory with a ECOG performance status 0 or 1.
* A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and beginning of vaccination.
* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented.

Exclusion Criteria:

* Tumor in a localization where a modest increase in size due to reactive oedema may have a large impact on patients neurological condition.
* Large tumor remnant after surgery.
* History of prior malignancy other than glioma, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB.
* Chronic active infection requiring antibiotic therapy.
* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.
* Prior splenectomy.
* Glucocorticoid treatment not possible to terminate due to autoimmune disease or increased intracranial pressure.
* Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.
* History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.
* Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination.
* Pregnancy or lactation.
* Any reason why, in the opinion of the investigator, the patient should not participate.
A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis

With IRB approval and informed consent, patients (n=10) (18-50 years old) with post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty will be enrolled in the study. Primary criteria for inclusion will be Grade IV changes in the articular cartilage of the femoral condyle and tibial plateau and meniscal pathology in the medial or lateral femorotibial joint as determined by physical examination, diagnostic imaging and knee arthroscopy by the PI. Exclusion criteria include Grade III or IV changes in any other compartment of the knee, acute injury to any other part of the affected lower extremity, or inability to comply with the protocol.

After enrollment, patients will undergo standardized knee radiography, and complete assessments (described below). Size-matched (standard clinical methodology) proximal tibia with meniscus and distal femur allografts from the same donor will be obtained from a tissue bank (Musculoskeletal Transplant Foundation, Edison, NJ) who has licensed the MOPS technology. The medial or lateral femoral condyle will be replaced using our novel instrumentation and technique described above. Tibial plateau-meniscus grafts will be trimmed and used to replace the entire medial or lateral tibial condyle while sparing the attachments of ACL, PCL and respective collateral ligament. The tibial plateau graft will be fixated using commercial available implants used for bone fixation. In the event that the meniscus has been detached from the tibial plateau during graft harvest, the periphery of the meniscus will be sutured to the capsule following standard meniscus transplant procedure.

Patients will undergo controlled post-operative rehabilitation according to standard protocols for osteochondral with concurrent meniscus allografts.

Range of motion, VAS pain score, SF-12, Tegner score, International Knee Documentation Committee (IKDC) subjective and objective scores, PROMIS Bank v1.2 - Physical Function-Mobility, PROMIS v1.1 - Global Health, PROMIS Bank v1.1- Pain Interference, PROMIS Bank v1.2 - Physical Function and Marx score as well as complete radiographs of the affected knee will be obtained prior to surgery and at 6 weeks, 3 months, 6 months, and 12 months after surgery to evaluate healing, function and evidence for arthrosis.


Eligibility Criteria:
Inclusion Criteria:

1. Patient requiring repair via tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
2. The subject is able and willing to consent to participate in the study

Exclusion Criteria:

1. Acute injury to any other part of the affected lower extremity
2. The subject is unwilling, or unable to consent due to psychiatric condition or legal incompetence
3. BMI \> 40
4. Age \> 50 at the time of enrollment
5. The subject is either pregnant, or a prisoner
6. Currently involved in a workers' compensation case at the time of enrollment
Comparison of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women

The purpose of this study is to comparison the effect of acupuncture and Fluoxetine on improvement quality of life among menopausal women.

This clinical trial is designed in two arm include acupuncture and fluoxetine group to evaluate the effect of these intervention on improvement quality of life among menopausal women.

Eligibility Criteria:
Inclusion Criteria:

* Last menstrual cycle 12 months ago
* natural menopause
* 4 episodes of hot flash daily
* follicle stimulating hormone (FSH)= 30-110 IU/L , E2\<18pg/ml
* thyroid-stimulating hormone(TSH)= 0.4-4/0 IU/ml
* No using of herbal agent for treatment of hot flash
* having score in Beck depression Inventory\<10
* No existence of any medical problems and using drugs

Exclusion Criteria:

* Not completing all acupuncture sessions
* Not completing fluoxetine admission
* Withdraw the study
A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma

The study will follow a group of patients with glaucoma disease that undergo a surgical procedure intended to reduce the intra-ocular pressure (IOP) for a period of one year.


Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe open angle glaucoma
* Central corneal thickness between 480 and 610 microns

Exclusion Criteria:

* surgical history of corneal graft
* presence of corneal opacities
* Failed prior trabeculectomy
Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)

The primary purpose of the protocol is to evaluate the adaptive optics visual simulator to measure optical aberrations in hyperopic eyes.

The study hypotheses are the:

* Ability to measure optical aberrations in hypermetropia.
* Knowledge of optical aberrations of the eye hyperopic.
* To adapt therapeutic management in optical aberrations measured.

The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.

Eligibility Criteria:
Inclusion Criteria:

* hyperopic patients
* to be able to understand an information and give a consent
* affiliated to medical insurance

Exclusion Criteria:

* pregnant women or nursing mothers
* ocular infection
* keratitis
* restless patients
* ocular surgery 90 days before inclusion
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.


Eligibility Criteria:
Inclusion Criteria:

* ages 18 - 70 years of age
* diagnosis of primary axillary hyperhidrosis
* HDSS score of ≥3
* threshold sweat production/axilla in 5 minutes as measured gravimetrically
* willingness to shave underarms prior to each study visit

Exclusion Criteria:

* botulinum toxin treatment in the prior 6 months
* signs of infection in the axilla
* skin affliction in the axilla requiring medical treatment
* oral anticholinergic treatment
* use of antiperspirants, deodorants, powders, or lotions
* use of axillary depilatories or axillary epilation
* history of surgery or other interventions for axillary hyperhidrosis
* female subjects who are pregnant or are nursing a child
A New Method for Estimating Dynamic Intrinsic PEEP

Dinamic intrinsic PEEP is

Dynamic intrinsic positive end-expiratory pressure (PEEPi dyn) play an important pathophysiology role in many acute respiratory pathologies.

The most accurate method to quantify PEEPi dyn is to measure the rise in transdiaphragmatic pressure (Pdi) at end expiration at the point of the contraction of the inspiratory muscles until inspiratory flow starts.

Such method, however, is invasive, poor comfortable and require patient active collaboration.

The purpose of this study is describe a new non-invasive method for estimate PEEPi dyn and validate this method with gold-standard-one.

Eligibility Criteria:
Inclusion Criteria:

* Acute or chronic respiratory failure
* Age \>=18 y

Exclusion Criteria:

* Lack of informed consent
* Controindication to the placement of oesophageal and gastric catheter:

esophageal varices, gastric or oesophageal bleeding in the previous 30 days, gastric or oesophageal surgery in the preceding year.

* Cardiac arrest
* Severe emodinamic instability (\> 1 vasoacttive drug)
* Acute coronary syndrome (AMI/UA)
* Inability to protect airway
* Respiratory arrest
* Pregnancy suspected or confirmed
* Diaphragm palsy
* Curarization in the preceding five hours
* Mechanical ventilation in controlled mode.
Humidity Under Continuous Positive Airway Pressure

Heated humidification in CPAP therapy is often not enough to prevent side effects like dryness of nasal mucosa and xerostomia, especially in cases of mouth breathing or mask leakage. Additionally a higher level of humidification in lower ambient room temperature can lead to condensation and irritating noises. Compliance of affected patients decreases considerably. Regarding this, devices with humidifier and additional heated tubing are developed to automatically regulate optimal humidification and temperature right up to the mask. The efficacy of a system with controlled heated humidification and heated tubing in nasal masks under various conditions like leakage and different pressure levels is object of this study.

Participants will breath 3 hours during daytime with a nasal mask under three different humidity modes (No humidity, controlled heated humidification, controlled heated humidification with heated tubing) with CPAP 8 and 12 mmHg and with and without leakage. The ambient room temperature is controlled with air conditioning. Changes in temperature and humidity is measured inside of the mask with a humidity sensor and recorded. After each phase the participants subjective opinion about humidity and temperature is asked.

Eligibility Criteria:
Inclusion Criteria:

* Age 20-70
* Obstructive Sleep Apnoea Syndrome

Exclusion Criteria:

* Other severe acute or chronic nasal disease (rhinitis, sinusitis), Cardiovascular disease, respiratory or neurologic disease
* Incapable of giving consent